NEW YORK (TheStreet) -- Shares of Aratana Therapeutics (PETX) - Get Aratana Therapeutics, Inc. Report are climbing by 12.48% to $5.86 on heavy trading volume Thursday afternoon, as the pet therapeutics company said it will present pivotal efficacy and safety data about its galliprant tablets for dogs.
The Leawood, KS-based company will present at the American Animal Hospital Association annual conference in Austin on Saturday.
Galliprant was approved by the FDA's Center for Veterinary Medicine on March 20 for the control of pain and inflammation associated with osteoarthritis in dogs.
The therapeutic is expected to be available to veterinarians in the autumn of this year.
Aratana is focused on licensing, developing and commercializing biopharmaceutical products for companion animals.
About 1.11 million of the company's shares were traded by this afternoon vs. its average volume of 793,883 shares per day.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by several weaknesses, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: PETX